GRACELL BIOTECHNOLOGIES INC's ticker is GRCL and the CUSIP is 38406L103. A total of 34 filers reported holding GRACELL BIOTECHNOLOGIES INC in Q1 2023. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $28,517,587 | -24.4% | 9,901,940 | 0.0% | 0.17% | -22.0% |
| Q2 2023 | $37,726,391 | +104.8% | 9,901,940 | 0.0% | 0.22% | +100.0% |
| Q1 2023 | $18,417,608 | -19.1% | 9,901,940 | 0.0% | 0.11% | -18.0% |
| Q4 2022 | $22,774,462 | -28.6% | 9,901,940 | 0.0% | 0.13% | -30.4% |
| Q3 2022 | $31,884,247 | -41.5% | 9,901,940 | 0.0% | 0.19% | -35.9% |
| Q2 2022 | $54,460,670 | +136.1% | 9,901,940 | 0.0% | 0.30% | +207.2% |
| Q1 2022 | $23,071,520 | -61.4% | 9,901,940 | 0.0% | 0.10% | -55.1% |
| Q4 2021 | $59,808,000 | -56.5% | 9,901,940 | 0.0% | 0.22% | -55.1% |
| Q3 2021 | $137,340,000 | +3914.6% | 9,901,940 | +3662.7% | 0.48% | +4272.7% |
| Q2 2021 | $3,421,000 | -15.6% | 263,158 | 0.0% | 0.01% | -31.2% |
| Q1 2021 | $4,053,000 | – | 263,158 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 3,445,973 | $8,029,000 | 0.68% |
| Paradigm Biocapital Advisors LP | 783,445 | $1,825,000 | 0.48% |
| Orbimed Advisors | 7,884,870 | $18,372,000 | 0.30% |
| Vivo Capital, LLC | 961,359 | $2,240,000 | 0.15% |
| EcoR1 Capital, LLC | 1,559,710 | $3,634,000 | 0.11% |
| Temasek Holdings (Private) Ltd | 9,901,940 | $23,071,520 | 0.10% |
| Capital International, Inc./CA/ | 2,335,476 | $5,442,000 | 0.06% |
| Virtus ETF Advisers LLC | 24,728 | $58,000 | 0.03% |
| Capital International Sarl | 228,149 | $532,000 | 0.03% |
| FEDERATED HERMES, INC. | 1,298,578 | $3,026,000 | 0.01% |